PERSPECTA

News from every angle

← Back to headlines

Summit Therapeutics Ends 2025 with Strong Financials

Summit Therapeutics concluded 2025 with robust cash reserves and increased investment in its clinical development programs.

3 Mar, 07:21 — 3 Mar, 07:21
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual185d ago

Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment

Read full article →

Related Stories

Japan and U.S. Advance $550 Billion Investment Pact Focused on AI and Chips

22m ago

Stock Markets Drop Following Strong U.S. Jobs Report

1h ago

Anthropic Delays AI Startup IPO to Mid-October Amid Credit Facility Deal

2h ago

Trade Negotiations Stall as U.S. Halts Antitrust Cooperation With Canada

3h ago